A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
Public ClinicalTrials.gov record NCT01532869. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis
Study identification
- NCT ID
- NCT01532869
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 87 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- tocilizumab [RoActemra/Actemra] Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2012
- Primary completion
- Dec 31, 2013
- Completion
- Jul 31, 2015
- Last update posted
- Sep 22, 2016
2012 – 2015
United States locations
- U.S. sites
- 21
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90025 | — |
| Not listed | San Diego | California | 44122 | — |
| Not listed | Stanford | California | 94305-5317 | — |
| Not listed | Farmington | Connecticut | 06030 | — |
| Not listed | Washington D.C. | District of Columbia | 20007 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Baltimore | Maryland | 21224 | — |
| Not listed | Boston | Massachusetts | 02118 | — |
| Not listed | Ann Arbor | Michigan | 48109-0934 | — |
| Not listed | New Brunswick | New Jersey | 08903 | — |
| Not listed | Lake Success | New York | 11042 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Toledo | Ohio | 43614 | — |
| Not listed | Oklahoma City | Oklahoma | 73103 | — |
| Not listed | Philadelphia | Pennsylvania | 19131 | — |
| Not listed | Pittsburgh | Pennsylvania | 15261 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Salt Lake City | Utah | 84132 | — |
| Not listed | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01532869, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 22, 2016 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01532869 live on ClinicalTrials.gov.